Analyst Price Targets — TMCI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:35 pm | — | Stifel Nicolaus | $3.00 | $2.92 | TheFly | Treace Medical price target lowered to $3 from $5 at Stifel |
| December 18, 2025 2:15 pm | Richard Newitter | Truist Financial | $3.00 | $2.54 | TheFly | Treace Medical price target lowered to $3 from $4 at Truist |
| November 10, 2025 3:07 pm | Richard Newitter | Truist Financial | $4.00 | $3.86 | TheFly | Treace Medical price target lowered to $4 from $7 at Truist |
| October 15, 2025 12:47 pm | — | Truist Financial | $7.00 | $6.20 | TheFly | Treace Medical price target lowered to $7 from $8 at Truist |
| September 3, 2025 7:58 pm | — | Truist Financial | $8.00 | $7.25 | TheFly | Treace Medical price target raised to $8 from $6.60 at Truist |
| March 13, 2025 12:19 pm | — | Truist Financial | $9.50 | $7.94 | TheFly | Treace Medical price target lowered to $9.50 from $10 at Truist |
| February 4, 2025 11:06 am | Ryan Zimmerman | BTIG | $16.00 | $10.51 | TheFly | Treace Medical upgraded to Buy from Neutral at BTIG |
| December 31, 2024 12:45 pm | Ben Haynor | Lake Street | $14.50 | $7.44 | TheFly | Treace Medical initiated with a Buy at Lake Street |
| May 16, 2024 4:36 am | Danielle Antalffy | UBS | $6.50 | $5.95 | TheFly | Treace Medical downgraded to Neutral from Buy at UBS |
| September 21, 2022 9:19 am | — | BTIG | $28.00 | $23.95 | Benzinga | BTIG Maintains Buy on Treace Medical Concepts, Raises Price Target to $28 |
Latest News for TMCI
SAN DIEGO, July 13, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI) against certain of its officers and directors for alleged breaches of fiduciary duty.
New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base New portfolio addition to drive further penetration into incremental procedures throughout the foot and ankle; strengthens Treace's comprehensive suite of technologies for its growing customer base
PONTE VEDRA, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced it will present at the Sidoti Small Cap Conference, Thursday, June 18, 2026, beginning at approximately 1:45 pm ET.
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Treace Medical Concepts, Inc. (NASDAQ: TMCI). The investigation focuses on Treace's executive officers and whether investor losses may be recovered under federal securities laws.
Treace Medical Concepts NASDAQ: TMCI reaffirmed its full-year 2026 revenue outlook after reporting a first-quarter revenue decline, as management said new product adoption is helping drive procedure volume momentum despite pricing and mix headwinds.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TMCI.
U.S. House Trading
No House trades found for TMCI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.